bioAffinity Technologies (BIAF) Accumulated Expenses (2021 - 2026)

bioAffinity Technologies has disclosed Accumulated Expenses across 6 years of filings, most recently posting $2.0 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 118.18% year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $2.0 million (up 118.18% YoY), while the FY2025 annual figure was $1.7 million, up 59.1% from the prior year.
• Accumulated Expenses grew to $2.0 million in Q1 2026, from $1.7 million in the prior quarter.
• Over the last five years, Accumulated Expenses for BIAF reached as high as $2.0 million in Q1 2026 and fell as low as $281085.0 in Q1 2023.
• The 5-year median for Accumulated Expenses is $969093.0 (2024), against an average of $1.0 million.
• Annual changes were most pronounced in 2023 — Accumulated Expenses tumbled 59.76% — and 2024, when it soared 214.25%.
• A 5-year view of Accumulated Expenses shows it stood at $541894.0 in 2022, then surged by 112.18% to $1.1 million in 2023, then dropped by 6.09% to $1.1 million in 2024, then soared by 59.1% to $1.7 million in 2025, then increased by 18.39% to $2.0 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $2.0 million, $1.7 million, and $984547.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.